WALTHAM, Mass.--(BUSINESS WIRE)--March 15, 2006--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it presented an update on the development of its DirectSelect(TM) technology at the Drug Discovery Technology Europe 2006 meeting in London, United Kingdom. The Company’s presentation was delivered earlier today by Barry Morgan, Ph.D., Vice President, Chemistry. Dr. Morgan presented an overview of the development of DirectSelect(TM) technology, which included a discussion regarding both the generation of a set of libraries comprising over five billion compounds geared towards the identification of small molecule drug candidates, as well as the application of these libraries towards the identification of hit families to four well-known targets in proof-of-concept studies. A copy of the presentation has been posted on the Company’s website at http://www.praecis.com under “Investors.”
